CurrentNeighborhood Health Plan of Rhode IslandPolicy 2139-A

Coverage Criteria for peginterferon alfa-2a (Pegasys)

Defines clinical coverage, limitations, and authorization durations for peginterferon alfa-2a (Pegasys) across hepatitis and select hematologic/oncologic indications for Neighborhood Health Plan of Rhode Island members.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyCoverage Criteria for peginterferon alfa-2a (Pegasys)

Policy CodePolicy 2139-A

Change TypeNo material change

Effective Date

Next Review Date

Key ActionObtain prior authorization with required documentation demonstrating ongoing benefit and meet indication-specific criteria for requested duration.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Up to 48wHBV auth duration

12 moMost non-HBV auth

CoveredLiver transplant continuation

ListedMyeloproliferative neoplasm

Coverage Criteria for peginterferon alfa-2a (Pegasys)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Chronic Hepatitis C (CHC): In combination therapy with other hepatitis C virus (HCV) drugs for adults with compensated liver disease. Pegasys monotherapy is indicated only if the patient has a contraindication or significant intolerance to other HCV drugs. In combination with ribavirin for pediatric patients 5 years of age and older with compensated liver disease.

Refer to the regimen SGM for specific criteria and approval durations.

Chronic Hepatitis B (CHB): Treatment for infection in patients who have compensated liver disease and evidence of viral replication and liver inflammation. Includes treatment of non‑cirrhotic pediatric patients 3 years of age and older with HBeAg‑positive CHB and elevated ALT.Authorization of up to 48 weeks may be granted

Includes HDV coinfection per policy.

Chronic HEV in Liver Transplant Recipients: Authorization of 12 months may be granted for treatment of chronic HEV infection when both of the following are met: (1) member is a liver transplant recipient; and (2) member has had an inadequate response, intolerance, or contraindication to ribavirin.12 months

Prior step requirement: inadequate response/intolerance/contraindication to ribavirin required.

Myeloproliferative Neoplasms: Authorization of 12 months may be granted for essential thrombocythemia, polycythemia vera, or symptomatic lower‑risk myelofibrosis.12 months

Continuation requires evidence of clinical benefit (e.g., morphological response, reduction or stabilization in spleen size, improvement of thrombocytosis/leukocytosis).

Other hematologic/oncologic and rare diseases: Authorization of 12 months may be granted for systemic mastocytosis; adult T‑cell leukemia/lymphoma; mycosis fungoides/Sezary syndrome; primary cutaneous CD30+ T‑cell lymphoproliferative disorders; hairy cell leukemia; Erdheim‑Chester disease; and chronic myeloid leukemia in pregnancy.12 months

Refer to individual regimen SGM for specific clinical criteria.

inv-02: Chronic viral hepatitis in liver transplant recipients — Continuation

Covered when ALL of the following are met

Chronic viral hepatitis in liver transplant recipients — continuation: Continuation of therapy for chronic HCV, chronic HBV (including HDV coinfection), or chronic HEV infection in liver transplant recipients is allowed when the member meets all requirements in the coverage criteria.

All members (including new members) requesting continuation must meet the coverage criteria.

inv-03: Myeloproliferative Neoplasm — Continuation

Authorization may be granted when the member is experiencing benefit

Myeloproliferative Neoplasm continuation: Authorization of 12 months may be granted if the member is experiencing benefit from therapy as evidenced by improvement in symptoms and/or disease markers (e.g., morphological response, reduction or stabilization in spleen size, improvement of thrombocytosis or leukocytosis).12 months

Documentation of clinical benefit is required for reauthorization.

inv-04: Systemic mastocytosis — Continuation

Authorization may be granted when the member is experiencing benefit

Systemic mastocytosis continuation: Authorization of 12 months may be granted if the member is experiencing benefit from therapy as evidenced by improvement in symptoms and/or disease markers (e.g., reduction in serum and urine metabolites of mast cell activation, improvement in cutaneous lesions, skeletal disease, or bone marrow mast cell burden).12 months

Documentation of clinical benefit is required for reauthorization.

inv-05: All other indications — Continuation

Authorization may be granted when ALL of the following are met

All other indications continuation: Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for all other indications in the coverage criteria section (not previously listed) when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.12 months

Members with evidence of unacceptable toxicity or disease progression while on the current regimen are excluded from 12‑month reauthorization.

Provider Requirements, Prior Authorization, and Continuation Rules

Denial Risk

Experimental/Investigational Exclusions

All other indications not listed under approved or compendial uses are considered experimental/investigational and are not medically necessary. Prior authorization will be denied for requests that do not meet an accepted indication.

Prior Authorization

Reference to Regimen-Specific Criteria and Continuation Requirements

Refer to the specific SGM (specialty/guideline module) for the requested regimen for detailed coverage criteria and exact approval durations. Approval durations and required documentation vary by regimen; providers must follow the regimen-specific criteria when submitting initial and continuation authorization requests.

See regimen-specific SGM for criteria and approval durations
Follow regimen requirements for both initial and continuation requests

Prior Authorization

Continuation Prior Authorization Requirement

Prior authorization is required for initiation and continuation of therapy. Continuation requests for chronic HCV, chronic HBV (including HDV coinfection), and chronic HEV in liver transplant recipients must meet all coverage criteria. Failure to meet continuation requirements may result in denial of the authorization.

Continuation requests must document ongoing benefit and lack of unacceptable toxicity
All members (including new members) requesting continuation must meet all coverage criteria

Note

Authorization Durations

Authorization durations vary by indication: up to 48 weeks total may be granted for chronic HBV (including HDV coinfection); 12 months may be granted for chronic HEV in liver transplant recipients (when criteria met), myeloproliferative neoplasms, systemic mastocytosis, and other listed indications when benefit is demonstrated.

Chronic HBV (including HDV): up to 48 weeks total
Chronic HEV in liver transplant recipients: up to 12 months when criteria met
Myeloproliferative neoplasms, systemic mastocytosis, and other listed indications: up to 12 months when benefit demonstrated

Documentation Required

Evidence of Benefit Required for Continuation

Documentation supporting continuation must demonstrate ongoing clinical benefit (for example, improvement in symptoms and/or disease markers) and absence of unacceptable toxicity or disease progression. Failure to provide adequate documentation may result in denial.

Evidence of benefit may include symptomatic improvement, morphological response, reduction/stabilization in spleen size, improvement in lab markers, or reduction in mast cell activation markers
Document absence of unacceptable toxicity or disease progression

Definitions and Compendial Uses

Compendial uses — supported indications

Supported compendial usesChronic hepatitis E virus infection; myeloproliferative neoplasms (essential thrombocythemia, polycythemia vera, symptomatic lower‑risk myelofibrosis); systemic mastocytosis; adult T‑cell leukemia/lymphoma; mycosis fungoides/Sezary syndrome; primary cutaneous CD30+ T‑cell lymphoproliferative disorders; hairy cell leukemia; Erdheim‑Chester disease; chronic myeloid leukemia.

Scope noteThese uses are listed as compendial indications supporting coverage when applicable approval criteria are met.

Exclusion reminderAll other indications not listed in the compendial or FDA‑approved uses are considered experimental/investigational and not medically necessary.

Myeloproliferative Neoplasm — definition and reauthorization criteria

TermMyeloproliferative Neoplasm

Typical covered subtypesEssential thrombocythemia; polycythemia vera; symptomatic lower‑risk myelofibrosis.

Continuation requirementAuthorization of 12 months may be granted if the member is experiencing benefit from therapy as evidenced by improvement in symptoms and/or disease markers (e.g., morphological response, reduction or stabilization in spleen size, improvement of thrombocytosis/leukocytosis).

Systemic mastocytosis — continuation evidence requirements

TermSystemic mastocytosis

Evidence of benefit required for continuationAuthorization of 12 months may be granted if the member is experiencing benefit from therapy as evidenced by improvement in symptoms and/or disease markers.

Examples of measurable benefitReduction in serum and urine metabolites of mast cell activation; improvement in cutaneous lesions; improvement in skeletal disease; reduction in bone marrow mast cell burden.

Background on peginterferon alfa-2a (Pegasys)

Background: Peginterferon alfa‑2a (Pegasys) is an interferon‑based antiviral and immunomodulatory agent used in combination regimens for treatment of chronic viral hepatitis and for certain hematologic and oncologic conditions supported by compendia. The policy lists FDA‑approved and compendial uses including treatment of chronic hepatitis C in combination with other HCV agents for adults with compensated liver disease (and with ribavirin for pediatric patients age ≥5 years), treatment of chronic hepatitis B in select patients, and compendial indications such as chronic hepatitis E infection and several myeloproliferative and lymphoid neoplasms. Clinical continuation and reauthorization decisions hinge on documented clinical benefit and absence of unacceptable toxicity or disease progression.